Abstract
Proteolysis or protein degradation is an important biological function which has been attributed to a major class of enzymes called proteases. In the living system, a fine-tuning between the activity of proteases and their counterparts can be seen, and disruption of this balance leads to the occurrence of various diseases including cancer. Several studies indicate that protease activity highly correlated with cancer advancement. The hallmarks of cancer like tissue evasion and metastasis, apoptosis, angiogenesis largely depend on proteolytic degradation and protease activation. Protease also contributes to avoidance of immune system, one of the emerging hallmarks in cancer progression. The immune system can recognize intracellular pathogens including cancer and elicits an effective immune response to restrict their activity and subsequently protect the host. In cancer microenvironment, immune cells are unable to recognize tumor neoantigens as well as incapable of inducing proper immune response for the clearance of tumor cells. Recent studies found that proteases not only promote tumor cell migration and metastasis it also encourages to maintain the tolerogenic tumor microenvironment by modulation of immune cell functions. Proteases are involved in several immune responses such as antigen processing and presentation, lymphocytes and neutrophil infiltration, activation of dendritic cells. The anomalies of protease actions dampen immune cell activities and establish immune tolerance. Inappropriate protease activities are responsible for inhibiting immunosurveillance and maintaining immune tolerance that ultimately leads to tumor immune evasion. Involvement of proteases in cancer suggests the use of protease inhibitors as anticancer drugs to targets not only tumor cells as well as tolerogenic immune cells to reeducate immune responses and reestablish immune surveillance. This chapter summarizes the current understanding of the interplay between proteases and the immune cells of the body and their involvement in cancer progression.
References
Rabinovich GA, Gabrilovich D, Sotomayor EM (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25:267–296
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3(11):991–998
Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329–360
Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86(3):353–364
Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331(6024):1565–1570
Kim R, Emi M, Tanabe K (2007) Cancer immunoediting from immune surveillance to immune escape. Immunology 121(1):1–14
Zou W (2005) Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nat Rev Cancer 5(4):263–274
Vinay DS, Ryan EP, Pawelec G et al (2015) Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol 35:S185–S198
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674
Kim R, Emi M, Tanabe K (2006) Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumor immunity. Immunology 119(2):254–264
López-Otín C, Overall CM (2002) Protease degradomics: a new challenge for proteomics. Nat Rev Mol Cell Biol 3(7):509–519
Fischer A (1946) Mechanism of the proteolytic activity of malignant tissue cells. Nature 6(157):442
Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2(3):161–174
Mohamed MM, Sloane BF (2006) Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 6(10):764–775
López-Otín C, Matrisian LM (2007) Emerging roles of proteases in tumor suppression. Nat Rev Cancer 7(10):800–808
Borgoño CA, Diamandis EP (2004) The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 4(11):876–890
Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295(5564):2387–2392
Overall CM, Kleifeld O (2006) Tumour microenvironment—opinion: validating matrix metal lo-proteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6(3):227–239
Turk B (2006) Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 5(9):785–799
Goetzl EJ, Banda MJ, Leppert D (1996) Matrix metalloproteinases in immunity. J Immunol 156(1):1–4
Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35(4):495–516
Hengartner MO (2000) The biochemistry of apoptosis. Nature 407:770–776
MacKenzie SH, Clark AC (2008) Targeting cell death in tumors by activating caspases. Curr Cancer Drug Targets 8(2):98–109
Cullen SP, Brunet M, Martin SJ (2010) Granzymes in cancer and immunity. Cell Death Differ 17:616–623
Walsh CM, Edinger AL (2010) The complex interplay between autophagy, apoptosis, and necrotic signals promotes T-cell homeostasis. Immunol Rev 236:95–109
Xing Y, Hogquist KA (2016) T-cell tolerance: central and peripheral. Cold Spring Harb Perspect Biol 4:a006957
Jameson SC et al (2005) Central tolerance: learning self-control in the thymus. Nat Rev Immunol 5:772–782
Ghavami S, Hashemi M, Ande SR, Yeganeh B, Xiao W, Eshraghi M, Bus CJ, Kadkhoda K, Wiechec E, Halayko AJ, Los M (2009) Apoptosis and cancer: mutations within caspase genes. J Med Genet 46:497–510
Mintern JD, Harris J et al (2015) Autophagy and immunity. Immunol Cell Biol 93:1–2
Nair U et al (2012) A role for Atg8–PE deconjugation in autophagosome biogenesis. Autophagy 8(5):780–793
Kaminskyy V, Zhivotovsky B et al (2012) Proteases in autophagy. Biochimi Biophys Acta (BBA)-Proteins Proteomics 1824(1):44–50
Yin F, Cadenas E et al (2015) Mitochondria: the cellular hub of the dynamic coordinated network. Antioxid Redox Signal 22(12):961–964
Lazarou M et al (2015) Keeping the immune system in check: a role for mitophagy. Immunol Cell Biol 93:3–10
Ma Y, Galluzzi L, Zitvogel L, Kroemer G et al (2013) Autophagy and cellular immune responses. Immunity 39
Bohovych I, Chan SS, Khalimonchuk O et al (2015) Mitochondrial protein quality control: the mechanisms guarding mitochondrial health. Antioxid Redox Signal 22(12):977–994
Brough D et al (2011) Understanding the mechanism of IL-1β secretion. Cytokine Growth Factor Rev 22(4):189–195
Wei L-X et al (2015) The role of autophagy induced by tumor microenvironment in different cells and stages of cancer. Cell Biosci 13578-015-0005-2
Crotzer VL, Blum JS et al (2009) Autophagy and its role in MHC-mediated antigen presentation. J Immunol 182(6):3335–3341
Rock KL, Farfán-Arribas DJ, Shen L et al (2010) Proteases in MHC class I presentation and cross-presentation. J Immunol 184(1):9–15
Mah LY, Ryan KM et al (2012) Autophagy and cancer. Cold Spring Harb Perspect Biol 4:a008821
Mellman I, Steinman RM (2001) Dendritic cells: specialized and regulated antigen processing machines. Cell 106:255–258
Norbury CC, Basta S, Donohue KB (2004) CD8+ T cell cross-priming via transfer of proteasome substrates. Science 304:1318–1321
Bromley SK, Burack WR, Johnson KG, Somersalo K, Sims TN, Sumen C, Davis MM, Shaw AS, Allen PM, Dustin ML (2001) The immunological synapse. Annu Rev Immunol 19:375
Bartmann J, Frankenberger M, Neurohr C, Eickelberg O, Noessner E, von Wulffen W (2016) A novel role of MMP-13 for murine DC function: its inhibition dampens T-cell activation. Int Immunol. doi:10.1093/intimm/dxw008
Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3:133–146
Quatromoni JG, Eruslanov E et al (2012) Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am J Transl Res 4(4):376–389
Solinas G et al (2009) Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 86(5):1065–1073
Kothari P et al (2014) IL-6-mediated induction of MMP-9 is modulated by JAK-dependent IL-10 expression in macrophages. J Immunol 192(1): 10.4049
Trikha P, Carson WE et al (2014) Signaling pathways involved in MDSC regulation. Biochim Biophys Acta 1846(1):55–65
Kessenbrock K, Plaks V, Werb Z et al (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141(1):52–67
Albeituni SH, Yan J et al (2013) Hampering the immune suppressors: therapeutic targeting of myeloid-derived suppressor cells (MDSC) in cancer. Cancer J 19(6):490–501
Parker KH et al (2015) Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment. Adv Cancer Res 128:95–139
Vérollet C, Charrière GM et al (2011) Extracellular proteolysis in macrophage migration: losing grip for a breakthrough. Eur J Immunol (10):2805–13
Chanmee T et al (2014) Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel) 6(3):1670–1690
Yang M et al (2014) Cathepsin S-mediated autophagic flux in tumor-associated macrophages accelerates tumor development by promoting M2 polarization. Mol Cancer 1476-4598-13-43
Shree T et al (2011) Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev 25(23):2465–2479
Rőszer T (2015) Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediat Inflamm 2015:816460
Nizet V et al (2009) Interdependence of hypoxic and innate immune responses. Nat Rev Immunol 9:609–617
Weidemann A, Johnson RS et al (2008) Biology of HIF-1α. Cell Death Differ 15:621–627
Lewis CE, Pollard JW et al (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res 66(2)
Blum JS, Wearsch PA, Cresswell P (2013) Pathways of antigen processing. Annu Rev Immunol 31:443–473
Seliger B (2008) Different regulation of MHC class I antigen processing components in human tumors. J Immunotoxicol 5:361–367
Maupin-Furlow J (2012) Proteasomes and protein conjugation across domains of life. Nat Rev Microbiol 10:100–111
Yewdell J, Lapham C, Bacik I, Spies T, Bennink J (1994) MHC-encoded proteasome subunits LMP2 and LMP7 are not required for efficient antigen presentation. J Immunol 152:1163–1170
Cabrera T, Maleno I, Collado A, Lopez Nevot MA, Tait BD, Garrido F (2007) Analysis of HLA class I alterations in tumors: choosing a strategy based on known patterns of underlying molecular mechanisms. Tissue Antigens 69(Suppl 1):264–268
Serwold T, Gonzalez F, Kim J, Jacob R, Shastri N (2002) ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature 419:480–483
Saric T, Chang SC, Hattori A, York IA, Markant S, Rock KL, Tsujimoto M, Goldberg AL (2002) An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat Immunol 3:1169–1176
Koopmann JO, Post M, Neefjes JJ, Hammerling GJ, Momburg F (1996) Translocation of long peptides by transporters associated with antigen processing (TAP). Eur J Immunol 26:1720–1728
Seliger B, Ritz U, Ferrone S (2006) Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int J Cancer 118:129–138
Nie Y, Yang G, Song Y, Zhao X, So C, Liao J, Wang LD, Yang CS (2001) DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. Carcinogenesis 22:1615–1623
Rodriguez T, Mendez R, Del Campo A, Jimenez P, Aptsiauri N, Garrido F, Ruiz-Cabello F (2007) Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines. BMC Cancer 7:34
Fruci D, Ferracuti S, Limongi MZ, Cunsolo V, Giorda E, Fraioli R, Sibilio L, Carroll O, Hattori A, van Endert PM, Giacomini P (2006) Expression of endoplasmic reticulum aminopeptidases in EBV-B cell lines from healthy donors and in leukemia/lymphoma, carcinoma, and melanoma cell lines. J Immunol 176:4869–4879
Kehlen A, Lendeckel U, Dralle H, Langner J, Hoang-Vu C (2003) Biological significance of aminopeptidase N/CD13 in thyroid carcinomas. Cancer Res 63:8500–8506
Menrad A, Speicher D, Wacker J, Herlyn M (1993) Biochemical and functional characterization of aminopeptidase N expressed by human melanoma cells. Cancer Res 53:1450–1455
Marks MS, Blum JS, Cresswell P (1990) Invariant chain trimers are sequestered in the rough endoplasmic reticulum in the absence of association with HLA class II antigens. J Cell Biol 111:839–855
Roche PA, Cresswell P (1990) Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding. Nature 345:615–618
Landsverk OJ, Bakke O, Gregers TF (2009) MHC II and the endocytic pathway: regulation by invariant chain. Scand J Immunol 70:184–193
Riberdy JM, Newcomb JR, Surman MJ, Barbosa JA, Cresswell P (1992) HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature 360:474–477
Mohan JF, Petzold SJ, Unanue ER (2011) Register shifting of an insulin peptide-MHC complex allows diabetogenic T cells to escape thymic deletion. J Exp Med 208:2375–2383
Pu Z, Lovitch SB, Bikoff EK, Unanue ER (2004) T cells distinguish MHC-peptide complexes formed in separate vesicles and edited by H2-DM. Immunity 20:467–476
Denzin LK, Cresswell P (1995) HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading. Cell 82:155–165
Kropshofer H, Vogt AB, Moldenhauer G, Hammer J, Blum JS, Hammerling GJ (1996) Editing of the HLA-DR-peptide repertoire by HLA-DM. EMBO J 15:6144–6154
Denzin LK, Sant’Angelo DB, Hammond C, Surman MJ, Cresswell P (1997) Negative regulation by HLA-DO of MHC class II-restricted antigen processing. Science 278:106–109
Ham H, Sreelatha A, Orth K (2011) Manipulation of host membranes by bacterial effectors. Nat Rev Microbiol 9:635–646
Muller S, Dennemarker J, Reinheckel T (2012) Specific functions of lysosomal proteases in endocytic and autophagic pathways. Biochim Biophys Acta 1824:34–43
Hsing LC, Rudensky AY (2005) The lysosomal cysteine proteases in MHC class II antigen presentation. Immunol Rev 207:229–241
Maric MA, Taylor MD, Blum JS (1994) Endosomal aspartic proteinases are required for invariant-chain processing. Proc Natl Acad Sci USA 91:2171–2175
Deussing J, Roth W, Saftig P, Peters C, Ploegh HL, Villadangos JA (1998) Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. Proc Natl Acad Sci USA 95:4516–4521
Tao K, Stearns NA, Dong J, Wu QL, Sahagian GG (1994) The proregion of cathepsin L is required for proper folding, stability, and ER exit. Arch Biochem Biophys 311:19–27
Coulombe R, Grochulski P, Sivaraman J, Menard R, Mort JS, Cygler M (1996) Structure of human procathepsin L reveals the molecular basis of inhibition by the prosegment. EMBO J 15:5492–5503
Turk B, Dolenc I, Lenarcic B, Krizaj I, Turk V, Bieth JG, Bjork I (1999) Acidic pH as a physiological regulator of human cathepsin L activity. Eur J Biochem 259:926–932
Nakagawa T, Roth W, Wong P, Nelson A, Farr A, Deussing J, Villadangos JA, Ploegh H, Peters C, Rudensky AY (1998) Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. Science 280:450–453
Shi GP, Villadangos JA, Dranoff G, Small C, Gu L, Haley KJ, Riese R, Ploegh HL, Chapman HA (1999) Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity 10:197–206
Manoury B, Hewitt EW, Morrice N, Dando PM, Barrett AJ, Watts C (1998) An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. Nature 396:695–699
Antoniou AN, Blackwood SL, Mazzeo D, Watts C (2000) Control of antigen presentation by a single protease cleavage site. Immunity 12:391–398
Manoury B, Mazzeo D, Fugger L, Viner N, Ponsford M, Streeter H, Mazza G, Wraith DC, Watts C (2002) Destructive processing by asparagine endopeptidase limits presentation of a dominant T cell epitope in MBP. Nat Immunol 3:169–174
Manoury B, Mazzeo D, Li DN, Billson J, Loak K, Benaroch P, Watts C (2003) Asparagine endopeptidase can initiate the removal of the MHC class II invariant chain chaperone. Immunity 18:489–498
Bevec T, Stoka V, Pungercic G, Dolenc I, Turk V (1996) Major histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L. J Exp Med 183:1331–1338
Zavasnik-Bergant V, Schweiger A, Bevec T, Golouh R, Turk V, Kos J (2004) Inhibitory p41 isoform of invariant chain and its potential target enzymes cathepsins L and H in distinct populations of macrophages in human lymph nodes. Immunology 112:378–385
Storm van’s Gravesande K, Layne MD, Ye Q, Le L, Baron RM, Perrella MA, Santambrogio L, Silverman ES, Riese RJ (2002) IFN regulatory factor-1 regulates IFN-gamma-dependent cathepsin S expression. J Immunol 168:4488–4494
Thibodeau J, Bourgeois-Daigneault MC, Lapointe R (2012) Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy. Oncoimmunology 1:908–916
Durrant LG, Ballantyne KC, Armitage NC, Robins RA, Marksman R, Hardcastle JD, Baldwin RW (1987) Quantitation of MHC antigen expression on colorectal tumours and its association with tumour progression. Br J Cancer 56:425–432
Tabibzadeh SS, Sivarajah A, Carpenter D, Ohlsson-Wilhelm BM, Satyaswaroop PG (1990) Modulation of HLA-DR expression in epithelial cells by interleukin 1 and estradiol-17 beta. J Clin Endocrinol Metab 71:740–747
Dazzi F, D’Andrea E, Biasi G, De Silvestro G, Gaidano G, Schena M, Tison T, Vianello F, Girolami A, Caligaris-Cappio F (1995) Failure of B cells of chronic lymphocytic leukemia in presenting soluble and alloantigens. Clin Immunol Immunopathol 75:26–32
Degener T, Momburg F, Moller P (1988) Differential expression of HLA-DR, HLA-DP, HLA-DQ and associated invariant chain (Ii) in normal colorectal mucosa, adenoma and carcinoma. Virchows Arch A Pathol Anat Histopathol 412:315–322
Thompson JA, Srivastava MK, Bosch JJ, Clements VK, Ksander BR, Ostrand-Rosenberg S (2008) The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes. Cancer Immunol Immunother 57:389–398
Frolich D, Blassfeld D, Reiter K, Giesecke C, Daridon C, Mei HE, Burmester GR, Goldenberg DM, Salama A, Dorner T (2012) The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression. Arthritis Res Ther 14:R54
Werle B, Staib A, Julke B, Ebert W, Zladoidsky P, Sekirnik A, Kos J, Spiess E (1999) Fluorometric microassays for the determination of cathepsin L and cathepsin S activities in tissue extracts. Biol Chem 380:1109–1116
Kos J, Sekirnik A, Kopitar G, Cimerman N, Kayser K, Stremmer A, Fiehn W, Werle B (2001) Cathepsin S in tumours, regional lymph nodes and sera of patients with lung cancer: relation to prognosis. Br J Cancer 85:1193–1200
Turk V, Turk B, Guncar G, Turk D, Kos J (2002) Lysosomal cathepsins: structure, role in antigen processing and presentation, and cancer. Adv Enzyme Regul 42:285–303
Felix K, Gaida MM (2016) Neutrophil-derived proteases in the microenvironment of pancreatic cancer—active players in tumor progression. Int J Biol Sci 12(3):302–313
Hajjar E, Broemstrup T, Kantari C, Witko-Sarsat V, Reuter N (2010) Structures of human proteinase 3 and neutrophil elastase–so similar yet so different. FEBS J277:2238–2254
Sun Z, Yang P (2004) Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression. Lancet Oncol 5:182–190
Gaida MM, Steffen TG, Gunther F, Tschaharganeh DF, Felix K, Bergmann F, Schirmacher P, Hansch GM (2012) Polymorphonuclear neutrophils promote dyshesion of tumor cells and elastase-mediated degradation of E-cadherin in pancreatic tumors. Eur J Immunol 42:3369–3380
Tan GJ, Peng ZK, Lu JP, Tang FQ (2013) Cathepsins mediate tumor metastasis. World J Biol Chem 4:91–101
Wiedow O, Meyer-Hoffert U (2005) Neutrophil serine proteases: potential key regulators of cell signalling during inflammation. J Intern Med 257:319–328
Padrines M, Wolf M, Walz A, Baggiolini M (1994) Interleukin-8 processing by neutrophil elastase, cathepsin G and proteinase-3. FEBS Lett 352:231–235
Chertov O, Ueda H, Xu LL, Tani K, Murphy WJ, Wang JM, Howard OM, Sayers TJ, Oppenheim JJ (1997) Identification of human neutrophil-derived cathepsin G and azurocidin/CAP37 as chemoattractants for mononuclear cells and neutrophils. J Exp Med 186:739–747
Valkovskaya N, Kayed H, Felix K, Hartmann D, Giese NA, Osinsky SP, Friess H, Kleeff J (2007) ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer. J Cell Mol Med 11:1162–1174
Stocker W, Bode W (1995) Structural features of a superfamily of zinc-endopeptidases: the metzincins. Curr Opin Struct Biol 5:383–390
Krampert M, Kuenzle S, Thai SN, Lee N, Iruela-Arispe ML, Werner S (2005) ADAMTS1 proteinase is up-regulated in wounded skin and regulates migration of fibroblasts and endothelial cells. J Biol Chem 280:23844–23852
Decock J, Obermajer N, Vozelj S, Hendrickx W, Paridaens R, Kos J (2008) Cathepsin B, cathepsin H, cathepsin X and cystatin C in sera of patients with early-stage and inflammatory breast cancer. Int J Biol Markers 23(3):161–168
Jevnikar Z, Obermajer N, Bogyo M, Kos J (2008) The role of cathepsin X in the migration and invasiveness of T lymphocytes. J Cell Sci 121(16):2652–2661
Lauffenburger DA, Horwitz AF (1996) Cell migration: a physically integrated molecular process. Cell 84(3):359–369
Kos J, Jevnikar Z, Obermajer N (2009) The role of cathepsin X in cell signaling. Cell Adh Migr 3(2):164–166
Bauer S, Groh V, Wu J (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727–729
Waldhauer I, Goehlsdorf D, Gieseke F, Weinschenk T, Wittenbrink M, Ludwig A, Stevanovic S, Rammensee HG, Steinle A (2008) Tumor-associated MICA Is Shed by ADAM proteases. Cancer Res 68(15):6368–6376
Ding Y, Xu D, Feng G, Bushell A, Muschel RJ, Wood KJ (2009) Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and −9. Diabetes 58:1797–1806
Lee BK, Kim MJ, Jang HS, Lee HR, Ahn KM, Lee JH, Choung PH (2008) A high concentration of MMP-2/gelatinase A and MMP-9/gelatinase B reduce NK cell-mediated cytotoxicity against an oral squamous cell carcinoma cell line. In Vivo 22:593–597
Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D (2004) Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103:4619–4621
Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, Baratelli F, Huang M, Batra RK, Dubinett SM (2005) Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res 65:5211–5220
Ma X, Kundu N, Rifat S, Walser T, Fulton AM (2006) Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res 66:2923–2927
Kundu N, Ma X, Holt D, Goloubeva O, Ostrand-Rosenberg S, Fulton AM (2009) Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function. Breast Cancer Res Treat 117:235–242
Peng YP, Zhang JJ, Liang WB, Tu M, Lu ZP, Wei JS, Jiang KR, Gao WT, Wu JL, Xu ZK, Miao Y, Zhu Y (2014) Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction. BMC Cancer 14:738
Liu Q, Sun Y, Rihn S, Nolting A, Tsoukas PN, Jost S, Cohen K, Walker B, Alter G (2009) Matrix metalloprotease inhibitors restore impaired NK cell-mediated antibody-dependent cellular cytotoxicity in human immunodeficiency virus type 1 infection. J Virol 83(17):8705–8712
Park Y, Jin HS, Aki D et al (2014) The ubiquitin system in immuneregulation. Adv Immunol 124:17–66
Malynn BA, Ma A (2010) Ubiquitin makes its mark on immune regulation. Immunity 33:843–852
Van Loosdregt J, Fleskens V, Fu J et al (2013) Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity. Immunity 39:259–271
Shen M, Schmitt S, Buac D et al (2013) Targeting the ubiquitin-proteasome system for cancer therapy. Expert Opin Ther Targets 17:1091–1108
Harhaj EW, Dixit VM (2011) Deubiquitinases in the regulation of NF-κB signaling. Cell Res 21:22–39
Coornaert B, Baens M, Heyninck K et al (2008) T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat Immunol 9:263–271
Düwel M, Welteke V, Oeckinghaus A et al (2009) A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains. J Immunol 182:7718–7728
Ferch U, Kloo B, Gewies A et al (2009) Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 206:2313–2320
Compagno M, Lim WK, Grunn A et al (2009) Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459:717–721
Schmitz R, Hansmann ML, Bohle V et al (2009) TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 206:981–989
Goedegebuure P, Mitchem JB, Porembka MR et al (2011) Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. Curr Cancer Drug Targets 11:734–751
Yu J, Du W, Yan F, Wang Y et al (2013) Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol 190:3783–3797
Shao B, Wei X, Luo M et al (2015) Inhibition of A20 expression in tumor microenvironment exerts anti-tumor effect through inducing myeloid-derived suppressor cells apoptosis. Sci Rep 5:16437
Stromnes IM, Blattman JN, Tan X et al (2010) Abrogating Cbl-b in effector CD8 (+) T cells improves the efficacy of adoptive therapy of leukemia in mice. J Clin Invest 120:3722–3734
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Panda, A.K., Chakraborty, S., Kajal, K., Roy, D., Sarkar, T., Sa, G. (2017). Role of Proteases in Tumor Immune Evasion. In: Chakraborti, S., Dhalla, N. (eds) Pathophysiological Aspects of Proteases. Springer, Singapore. https://doi.org/10.1007/978-981-10-6141-7_12
Download citation
DOI: https://doi.org/10.1007/978-981-10-6141-7_12
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-6140-0
Online ISBN: 978-981-10-6141-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)